These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 18820127)

  • 1. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
    Tse AN; Sheikh TN; Alan H; Chou TC; Schwartz GK
    Mol Pharmacol; 2009 Jan; 75(1):124-33. PubMed ID: 18820127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
    Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
    Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins.
    McNamara AV; Barclay M; Watson AJ; Jenkins JR
    Biochem Pharmacol; 2012 Feb; 83(3):355-67. PubMed ID: 22138446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1.
    Sugimoto K; Sasaki M; Isobe Y; Tsutsui M; Suto H; Ando J; Tamayose K; Ando M; Oshimi K
    Oncogene; 2008 May; 27(22):3091-101. PubMed ID: 18071310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 independent radio-sensitization of human lymphoblastoid cell lines by Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Fujii Y; Kato T; Kubota N; Fujimori A; Niwa O; Okayasu R
    Oncol Rep; 2010 Jan; 23(1):199-203. PubMed ID: 19956882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
    Tse AN; Klimstra DS; Gonen M; Shah M; Sheikh T; Sikorski R; Carvajal R; Mui J; Tipian C; O'Reilly E; Chung K; Maki R; Lefkowitz R; Brown K; Manova-Todorova K; Wu N; Egorin MJ; Kelsen D; Schwartz GK
    Clin Cancer Res; 2008 Oct; 14(20):6704-11. PubMed ID: 18927314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
    Tse AN; Schwartz GK
    Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells.
    Moran DM; Gawlak G; Jayaprakash MS; Mayar S; Maki CG
    Oncogene; 2008 Sep; 27(42):5567-77. PubMed ID: 18504430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.
    Vaseva AV; Yallowitz AR; Marchenko ND; Xu S; Moll UM
    Cell Death Dis; 2011 May; 2(5):e156. PubMed ID: 21562588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
    Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
    Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons.
    Flatten K; Dai NT; Vroman BT; Loegering D; Erlichman C; Karnitz LM; Kaufmann SH
    J Biol Chem; 2005 Apr; 280(14):14349-55. PubMed ID: 15699047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.
    Yu Q; La Rose J; Zhang H; Takemura H; Kohn KW; Pommier Y
    Cancer Res; 2002 Oct; 62(20):5743-8. PubMed ID: 12384533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.
    Yao Q; Weigel B; Kersey J
    Clin Cancer Res; 2007 Mar; 13(5):1591-600. PubMed ID: 17332306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38.
    Hapke G; Yin MB; Wu J; Frank C; Rustum YM
    Int J Oncol; 2002 Nov; 21(5):1059-66. PubMed ID: 12370755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
    Robles AI; Wright MH; Gandhi B; Feis SS; Hanigan CL; Wiestner A; Varticovski L
    Clin Cancer Res; 2006 Nov; 12(21):6547-56. PubMed ID: 17085670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.
    Yan Y; Spieker RS; Kim M; Stoeger SM; Cowan KH
    Oncogene; 2005 May; 24(20):3285-96. PubMed ID: 15735702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.
    Mak JP; Man WY; Chow JP; Ma HT; Poon RY
    Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis.
    Pan Y; Ren KH; He HW; Shao RG
    Cancer Biol Ther; 2009 Aug; 8(16):1559-66. PubMed ID: 19502782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis.
    Wang Y; Decker SJ; Sebolt-Leopold J
    Cancer Biol Ther; 2004 Mar; 3(3):305-13. PubMed ID: 14726685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.
    Levesque AA; Fanous AA; Poh A; Eastman A
    Mol Cancer Ther; 2008 Feb; 7(2):252-62. PubMed ID: 18281511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.